The Prognostic Significance of Collagen VI in Pancreatic Ductal Adenocarcinoma.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pancreas Pub Date : 2024-10-01 Epub Date: 2024-06-24 DOI:10.1097/MPA.0000000000002360

Ella Kesti, Emmy Borgmästars, Jaana Hagström, Harri Mustonen, Hanna Seppänen, Caj Haglund, Malin Sund

{"title":"The Prognostic Significance of Collagen VI in Pancreatic Ductal Adenocarcinoma.","authors":"Ella Kesti, Emmy Borgmästars, Jaana Hagström, Harri Mustonen, Hanna Seppänen, Caj Haglund, Malin Sund","doi":"10.1097/MPA.0000000000002360","DOIUrl":null,"url":null,"abstract":"Objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and lack of biomarkers. A rich desmoplastic tumor stroma is considered a hallmark of PDAC and previous studies have indicated upregulated expression of collagen VI (COL6) in PDAC. COL6 is shown to associate with prognosis in many cancers but has been less extensively studied in PDAC.Materials and methods: The expression of COL6 was analyzed by immunohistochemistry in tissue microarrays containing resected tumor tissue samples from PDAC patients (n = 164). Significance of COL6 was estimated with Kaplan-Meier survival estimates and multivariable Cox regression analysis. COL6 protein and mRNA expression patterns were further investigated in publicly available datasets.Results: There were no statistically significant ( P < 0.05) differences in survival when comparing high and low protein expression of any of the analyzed COL6 α-chains (α1(VI): hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.64-1.28; α2(VI): HR 1.28, 95% CI 0.86-1.89; α3(VI): HR 0.91, 95% CI 0.64-1.29). Similar results were obtained when assessing public data from the Cancer Proteome Atlas, Clinical Proteomic Tumor Analysis Consortium, and The Cancer Genome Atlas.Conclusions: In contrast with previous studies and some other cancers, we did not find any association of COL6 tissue expression and PDAC survival.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002360","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and lack of biomarkers. A rich desmoplastic tumor stroma is considered a hallmark of PDAC and previous studies have indicated upregulated expression of collagen VI (COL6) in PDAC. COL6 is shown to associate with prognosis in many cancers but has been less extensively studied in PDAC.

Materials and methods: The expression of COL6 was analyzed by immunohistochemistry in tissue microarrays containing resected tumor tissue samples from PDAC patients (n = 164). Significance of COL6 was estimated with Kaplan-Meier survival estimates and multivariable Cox regression analysis. COL6 protein and mRNA expression patterns were further investigated in publicly available datasets.

Results: There were no statistically significant ( P < 0.05) differences in survival when comparing high and low protein expression of any of the analyzed COL6 α-chains (α1(VI): hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.64-1.28; α2(VI): HR 1.28, 95% CI 0.86-1.89; α3(VI): HR 0.91, 95% CI 0.64-1.29). Similar results were obtained when assessing public data from the Cancer Proteome Atlas, Clinical Proteomic Tumor Analysis Consortium, and The Cancer Genome Atlas.

Conclusions: In contrast with previous studies and some other cancers, we did not find any association of COL6 tissue expression and PDAC survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胰腺导管腺癌中胶原蛋白 VI 的预后意义。

目的：胰腺导管腺癌（PDAC）预后不良，缺乏有效的诊断和预后生物标志物。丰富和活化的脱鳞肿瘤基质被认为是 PDAC 的标志，因此基质成分可能是新的预后生物标志物的来源。胶原蛋白 VI（COL6）的表达已被发现与多种癌症的预后有关，但对 PDAC 的研究还不太广泛。之前的一些研究表明，COL6在PDAC中表达上调，可能具有预后价值：本研究通过免疫组化方法分析了 164 例（n = 164）接受手术切除的 PDAC 患者肿瘤组织样本组织芯片（TMA）中 COL6 的表达。评分结果与临床数据相结合，并通过 Kaplan-Meier 生存估计和多变量 Cox 回归分析估算 COL6 的预后意义。在癌症蛋白质组图集（TCPA）数据集（103人）和临床肿瘤蛋白质组分析联盟（CPTAC）数据集（138人）中进一步研究了COL6蛋白的表达模式。通过癌症基因组图谱（TCGA），对PDAC组织中COL6 mRNA的表达进行了研究，形成了包含168例（n = 168）PDAC患者基因表达数据和相应临床变量的数据集：在这一大型PDAC TMA队列中，比较任何一种COL6 α链（α1(VI)：HR为0.90，95% CI为0.64-1.28；α2(VI)HR 1.28，95% CI 0.86-1.89；α3(VI)：HR 0.91，95%CI 0.64-1.29）。在TCPA、CPTAC和TCGA的公开数据中评估COL6的表达也得到了类似的结果：结论：与之前的研究和其他一些癌症形式相比，我们没有发现 COL6 组织表达与 PDAC 蛋白或 mRNA 水平的生存率有任何关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.